COVID-19:- EMERGING CONFECTIONS BETWEEN COVID 19 AND TROPICAL PATHOGEN
Various factors including comorbidities, risk of hospital acquired infections, use of immunosuppressive therapy; alterations of immune system by COVID-19 may be responsible for coinfections. Coronavirus infected individuals are at higher risk for having coinfections with other tropical pathogens. Care facilities to the patient suffering from coinfections with Coronavirus and other tropical are given. Patients can have coinfections with one or more pathogens along with COVID emerging simultaneously. Bacterial coinfections are the most common including Staphylococcus aureus and klebsiella pneumoniae.
Human Rhinovirus and human Adenovirus are most commonly known viral infections coexist with COVID pathogens. Coinfection with Mycobacterium tuberculosis is also well known infection coexist with COVID-19. Identification and timely management of patient with coinfection can contribute to improved health of COVID-19. Coinfections can potentially increase the morbidities and mortalities in patients during ongoing pandemic. Highest coinfection rates were from blood borne viruses. Many studies showed respiratory virus coinfection with COVID-19. From total cases of COVID-19 in Wuhan near about 5.8% cases were infected with other types of respiratory pathogens. According to information provided about the type of pathogen and viral coinfection prevalence, it is easier for health workers to make diagnosis and give appropriate management to treat the coinfection. Secondary infections and bacterial coinfections are most commonly seen in severe influenza. Undiagnosed coinfections may have severe clinical progression associated with increased risk of hospitalization and approach management criteria and mortalities. Hence the case report provides the investigations for implications of viral and bacterial and other tropical pathogens coinfections in COVID-19 outcomes clinically.